Cargando…
Multi-route applications of tranexamic acid to reduce blood loss after total knee arthroplasty: a randomized controlled trial
BACKGROUND: Perioperative bleeding during total knee arthroplasty (TKA) is an ongoing problem for surgeons. Intravenous or topical application of tranexamic acid (TXA) can effectively stop bleeding, but there is still no uniform standard for the best method of administration and dose. METHODS: From...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709093/ https://www.ncbi.nlm.nih.gov/pubmed/31348286 http://dx.doi.org/10.1097/MD.0000000000016570 |
_version_ | 1783446129284743168 |
---|---|
author | Zhang, Shenqi Wang, Chengbin Shi, Lei Xue, Qingyun |
author_facet | Zhang, Shenqi Wang, Chengbin Shi, Lei Xue, Qingyun |
author_sort | Zhang, Shenqi |
collection | PubMed |
description | BACKGROUND: Perioperative bleeding during total knee arthroplasty (TKA) is an ongoing problem for surgeons. Intravenous or topical application of tranexamic acid (TXA) can effectively stop bleeding, but there is still no uniform standard for the best method of administration and dose. METHODS: From October 2016 to September 2018, 218 patients with unilateral primary knee osteoarthritis requiring knee replacement were enrolled and randomly divided into four groups. Group 1 (n = 55) received intra-articular injection (IAI) of TXA and peri-articular injection (PAI) of placebo, group 2 (n = 55) received IAI of placebo and PAI of TXA, group 3 (n = 51) received IAI of TXA and PAI of TXA, and group 4 (n = 57) received double placebo (IAI of placebo and PAI of placebo). The demographic characteristics, surgical indices, hematological indices, wound healing history, and thromboembolic events were investigated. RESULTS: Eight patients were lost to follow-up and 210 patients were included in the analysis. The median TBLs in patients who received IAI of TXA and PAI of placebo and those who received IAI of placebo and PAI of TXA were 470.81 ml and 481.54 ml, respectively. These TBL levels were significantly higher compared to those in patients who received IAI of TXA and PAI of TXA (359.18 ml, P ≤ .001), but significantly lower compared to those in patients who received the double placebo (522.71 ml, P ≤ .001). Compared to other groups, more patients in the double placebo group needed a blood transfusion (P = .013). In the short-term, the double placebo group had higher VAS pain scores and less ROM after surgery (P = .011 and P = .001, respectively). In the long-term (6-month follow-up), there were no significant differences in ROM, VAS, DVT, PE, or wound-related complications. CONCLUSION: The combined use of IAI and PAI of TXA can significantly reduce the TBL and the need for blood transfusion without delaying wound healing or increasing the risk of DVT and PE. In the short-term after surgery, this combined method reduces the pain VAS scores and improves the ROM; however, there are no long-term effects on VAS and ROM. |
format | Online Article Text |
id | pubmed-6709093 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-67090932019-10-01 Multi-route applications of tranexamic acid to reduce blood loss after total knee arthroplasty: a randomized controlled trial Zhang, Shenqi Wang, Chengbin Shi, Lei Xue, Qingyun Medicine (Baltimore) Research Article BACKGROUND: Perioperative bleeding during total knee arthroplasty (TKA) is an ongoing problem for surgeons. Intravenous or topical application of tranexamic acid (TXA) can effectively stop bleeding, but there is still no uniform standard for the best method of administration and dose. METHODS: From October 2016 to September 2018, 218 patients with unilateral primary knee osteoarthritis requiring knee replacement were enrolled and randomly divided into four groups. Group 1 (n = 55) received intra-articular injection (IAI) of TXA and peri-articular injection (PAI) of placebo, group 2 (n = 55) received IAI of placebo and PAI of TXA, group 3 (n = 51) received IAI of TXA and PAI of TXA, and group 4 (n = 57) received double placebo (IAI of placebo and PAI of placebo). The demographic characteristics, surgical indices, hematological indices, wound healing history, and thromboembolic events were investigated. RESULTS: Eight patients were lost to follow-up and 210 patients were included in the analysis. The median TBLs in patients who received IAI of TXA and PAI of placebo and those who received IAI of placebo and PAI of TXA were 470.81 ml and 481.54 ml, respectively. These TBL levels were significantly higher compared to those in patients who received IAI of TXA and PAI of TXA (359.18 ml, P ≤ .001), but significantly lower compared to those in patients who received the double placebo (522.71 ml, P ≤ .001). Compared to other groups, more patients in the double placebo group needed a blood transfusion (P = .013). In the short-term, the double placebo group had higher VAS pain scores and less ROM after surgery (P = .011 and P = .001, respectively). In the long-term (6-month follow-up), there were no significant differences in ROM, VAS, DVT, PE, or wound-related complications. CONCLUSION: The combined use of IAI and PAI of TXA can significantly reduce the TBL and the need for blood transfusion without delaying wound healing or increasing the risk of DVT and PE. In the short-term after surgery, this combined method reduces the pain VAS scores and improves the ROM; however, there are no long-term effects on VAS and ROM. Wolters Kluwer Health 2019-07-26 /pmc/articles/PMC6709093/ /pubmed/31348286 http://dx.doi.org/10.1097/MD.0000000000016570 Text en Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 |
spellingShingle | Research Article Zhang, Shenqi Wang, Chengbin Shi, Lei Xue, Qingyun Multi-route applications of tranexamic acid to reduce blood loss after total knee arthroplasty: a randomized controlled trial |
title | Multi-route applications of tranexamic acid to reduce blood loss after total knee arthroplasty: a randomized controlled trial |
title_full | Multi-route applications of tranexamic acid to reduce blood loss after total knee arthroplasty: a randomized controlled trial |
title_fullStr | Multi-route applications of tranexamic acid to reduce blood loss after total knee arthroplasty: a randomized controlled trial |
title_full_unstemmed | Multi-route applications of tranexamic acid to reduce blood loss after total knee arthroplasty: a randomized controlled trial |
title_short | Multi-route applications of tranexamic acid to reduce blood loss after total knee arthroplasty: a randomized controlled trial |
title_sort | multi-route applications of tranexamic acid to reduce blood loss after total knee arthroplasty: a randomized controlled trial |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709093/ https://www.ncbi.nlm.nih.gov/pubmed/31348286 http://dx.doi.org/10.1097/MD.0000000000016570 |
work_keys_str_mv | AT zhangshenqi multirouteapplicationsoftranexamicacidtoreducebloodlossaftertotalkneearthroplastyarandomizedcontrolledtrial AT wangchengbin multirouteapplicationsoftranexamicacidtoreducebloodlossaftertotalkneearthroplastyarandomizedcontrolledtrial AT shilei multirouteapplicationsoftranexamicacidtoreducebloodlossaftertotalkneearthroplastyarandomizedcontrolledtrial AT xueqingyun multirouteapplicationsoftranexamicacidtoreducebloodlossaftertotalkneearthroplastyarandomizedcontrolledtrial |